COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses

COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study

Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.

Inclusion Criteria:

• Clinical diagnosis of Covid-19 infection by the patient's general practitioner and hospital doctor
• Clinical signs started less than 8 days ago.
• Virological confirmation
• Understanding and acceptance of the trial.
• Written agreement to participate in the trial

Exclusion Criteria:

• Pregnancy
• Breastfeeding
• Inability to comply with protocol
• Lack of written agreement